Organon (OGN) Q2 2025 earnings summary

Executive summary

• Second quarter 2025 revenue was $1.6 billion, down 1% year-over-year at constant currency, with net income of $145 million and adjusted EBITDA of $522 million (32.7% margin); adjusted diluted EPS was $1.00.

• Growth in Women's Health, fertility, biosimilars (notably HADLIMA), and VTAMA offset declines from Atozet and Singulair due to loss of exclusivity and pricing pressures.

• Strong free cash flow generation, with $525 million before one-time costs in H1 and $350 million reported, tracking toward a $900 million+ target for 2025.

• Restructuring initiatives included a 6% headcount reduction, targeting $200 million in annual savings, and $345 million in long-term debt repaid in Q2.

• Recent acquisitions include Dermavant and U.S. rights to Tofidence from Biogen, expanding the portfolio and supporting future growth.

Financial highlights

• Adjusted gross margin was 61.7% (non-GAAP) and 54.8% (GAAP) for Q2 2025, with margin impacted by price pressure and product mix.

• Adjusted EBITDA margin improved to 32.7% from 31.9% year-over-year, with operating expenses down 2-3% YTD.

• Diluted EPS for Q2 2025 was $0.56 (GAAP) and $1.00 (non-GAAP adjusted); net income was $145 million (GAAP), $261 million (non-GAAP adjusted).

• Free cash flow before one-time costs was $525 million in H1, with $350 million reported, up from the prior year.

• Cash and cash equivalents were $599 million; total debt was $8.90 billion as of June 30, 2025.

Outlook and guidance

• Full-year 2025 revenue guidance raised to $6.275–$6.375 billion, with adjusted EBITDA margin guidance affirmed at 31.0–32.0%.

• Ex-FX revenue growth expected between -1.2% and 0.3%; adjusted gross margin guidance unchanged at 60–61%.

• Interest expense for 2025 estimated at $510 million, expected to drop to $475 million in 2026; non-GAAP tax rate for 2025 guided at 22.5%-24.5%.

• Net leverage targeted below 4.0x by year-end 2025 and 3.5x or below by end of 2026.

• Ongoing restructuring and supply chain optimization initiatives are anticipated to deliver further cost savings.